Article

A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19

2020-12-02

Abstract excerpt

An uncontrolled increase in cytokine production may lead to systemic hyperinflammation, vascular hypo-responsiveness, increased endothelial permeability, hypercoagulation, multi-organ dysfunction and eventually death in moderate to severely ill COVID-19 patients. Targeting T-cells, an important driver of the hyperinflammatory response, in the treatment of COVID-19, could potentially reduce mortality and improve su...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 93c54326-b640-5f48-b4f6-a05463bd7842
DOI: 10.1101/2020.12.01.20239574

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19DOI 10.1101/2020.12.01.20239574Read

Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19Semantic proximity Read

Role of T1 Inflammatory Endotype in the Pathophysiology of Severe COVID-19Semantic proximity Read

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trialSemantic proximity Read

Proposed CoVid-19 Treatments: Lessons from the Inflammation & Cardiovascular Disease Theory.Semantic proximity Read

Timely Administration of Tocilizumab Improves Survival of Hospitalized COVID-19 PatientsSemantic proximity Read

Imbalanced Immune Response of T-Cell and B-Cell Subsets in Patients with Moderate and Severe COVID-19Semantic proximity Read

Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness.Semantic proximity Read

Predictive value of inflammatory factors and lymphocyte counts in tracheal intubation and death after infection with COVID-19Semantic proximity Read

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort studySemantic proximity Read

Immune targeted therapies for COVID-19 Infection: A Promising OutlookSemantic proximity Read

Overview of the pathogenesis of COVID‑19 (Review)Semantic proximity Read

A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir Vs Currently Used Therapy in Severe COVID-19 Adults. (COMVIVIR, clinicaltrials.gov NCT04475991)Semantic proximity Read